Abstract
Introduction.
Heart failure and type 2 diabetes mellitus are critical public health issues.
Objective.
To characterize the risk factors for mortality in patients with heart failure and type 2 diabetes mellitus from a large registry in Colombia and to evaluate the potential effect modifications by type 2 diabetes mellitus over other risk factors.
Materials and methods.
Heart failure patients with and without type 2 diabetes mellitus enrolled in the Registro Colombiano de Falla Cardíaca (RECOLFACA) were included.
RECOLFACA enrolled adult patients with heart failure diagnosis from 60 medical centers in Colombia during 2017-2019. The primary outcome was all-cause mortality. Survival analysis was performed using adjusted Cox proportional hazard models.
Results.
A total of 2514 patients were included, and the prevalence of type 2 diabetes mellitus was 24.7% (n = 620). We found seven independent predictors of short-term mortality for the general cohort, chronic obstructive pulmonary disease, sinus rhythm, triple therapy, nitrates use, statins use, anemia, and hyperkalemia. In the type 2 diabetes mellitus group, only the left ventricle diastolic diameter was an independent mortality predictor (HR = 0.96; 95% CI: 0.93-0.98). There was no evidence of effect modification by type 2 diabetes mellitus on the relationship between any independent predictors and all-cause mortality.
However, a significant effect modification by type 2 diabetes mellitus between smoking and mortality was observed.
Conclusions.
Patients with type 2 diabetes mellitus had higher mortality risk. Our results also suggest that type 2 diabetes mellitus diagnosis does not modify the effect of the independent risk factors for mortality in heart failure evaluated. However, type 2 diabetes mellitus significantly modify the risk relation between mortality and smoking in patients with heart failure.
Keywords: Diabetes mellitus; diabetes mellitus, type 2; heart failure; risk factors; mortality; Latin America; Colombia
Resumen
Introducción.
La insuficiencia cardíaca y la diabetes mellitus de tipo 2 son problemas críticos de salud pública.
Objetivo.
Caracterizar los factores de riesgo de mortalidad en pacientes con insuficiencia cardíaca y la diabetes mellitus de tipo 2 de un registro grande en Colombia y evaluar las posibles modificaciones del efecto de la diabetes mellitus de tipo 2 sobre otros factores de riesgo.
Materiales y métodos.
Se incluyeron pacientes con insuficiencia cardíaca con y sin diabetes mellitus de tipo 2, inscritos en el Registro Colombiano de Insuficiencia Cardíaca (RECOLFACA). RECOLFACA incorporó pacientes adultos con diagnóstico de insuficiencia cardíaca de 60 centros médicos de Colombia durante 2017-2019. El resultado primario fue la mortalidad por todas las causas. El análisis de supervivencia se realizó utilizando modelos ajustados de riesgos proporcionales de Cox.
Resultados.
Se incluyeron 2.514 pacientes, la prevalencia de diabetes mellitus de tipo 2 fue del 24,7 % (n = 620). Encontramos siete predictores independientes de mortalidad a corto plazo para la enfermedad pulmonar obstructiva crónica del grupo sin diabetes mellitus de tipo 2, el ritmo sinusal, la terapia triple, el uso de nitratos, el uso de estatinas, la anemia y la hiperpotasemia. En el grupo de diabetes mellitus de tipo 2, solo el diámetro diastólico del ventrículo izquierdo fue un predictor de mortalidad independiente (HR = 0,96; IC95 %: 0,93 - 0,98). No hubo evidencia de modificación del efecto de la diabetes mellitus de tipo 2 sobre la relación entre ningún predictor independiente y la mortalidad por todas las causas. Sin embargo, se observó una modificación significativa del efecto de la diabetes mellitus de tipo 2 entre el tabaquismo y la mortalidad.
Conclusiones.
Los pacientes con diabetes mellitus de tipo 2 tuvieron mayor riesgo de mortalidad. Los resultados también sugieren que el diagnóstico de diabetes mellitus de tipo 2 no modifica el efecto de los factores de riesgo independientes de mortalidad en IC evaluados. Sin embargo, la diabetes mellitus de tipo 2 modifica significativamente la relación de riesgo entre mortalidad y tabaquismo en pacientes con insuficiencia cardíaca, posiblemente debido a un efecto sinérgico negativo que resulta en lesión vascular.
Palabras clave: diabetes mellitus, diabetes mellitus de tipo 2, insuficiencia cardiaca, factores de riesgo, mortalidad, América Latina, Colombia
Heart failure and type 2 diabetes mellitus represent two of the most relevant non-transmissible chronic diseases worldwide, representing a critical public health issue nowadays 1. An estimated 6.2 million individuals were living with heart failure in the United States between 2013 and 2016, while its prevalence in Latin American countries was 1% [95% confidence interval (95%CI): 0.1%- 2.7%) between 1994 and 2014 2,3. Moreover, approximately 26 million people are affected by heart failure worldwide, representing an estimated health expenditure of around USD $31 billion by 2012, which is expected to increase by 127% by 2030 3. On the other hand, an estimated 462 million individuals have been diagnosed with type 2 diabetes mellitus by 2017, reflecting a prevalence rate of 6059 cases per 100,000 population. Moreover, around one million deaths per year can be attributed to diabetes alone, positioning this disease as the ninth leading cause of mortality worldwide 4.
Heart failure and type 2 diabetes mellitus commonly coexist, exponentially increasing the risk of complications in the patients affected by both conditions 5. This coexistence is derived from the common pathophysiological pathways both heart failure and type 2 diabetes mellitus share 1,6. This association was first observed in the Framingham study after more than 40 years of follow-up. In this cohort, men and women with diabetes mellitus had a two- and five-times higher risk of developing heart failure compared to the general population, respectively 7. These findings could partially explain why the prevalence of type 2 diabetes mellitus in heart failure patients is exceptionally high (estimated to be around 30% to 50%) 5. However, a new hypothesis suggesting a bidirectional relation between heart failure and type 2 diabetes mellitus has also been gaining relevance in recent years, giving further explanation to this observed prevalence, and highlighting the importance of type 2 diabetes mellitus and heart failure coexistence 1.
In this context, type 2 diabetes mellitus can modify heart failure’s disease course, increasing the risk of adverse outcomes, including rehospitalizations, prolonged hospital stays, and even mortality, mainly in the context of heart failure with reduced ejection fraction 8,9. Nonetheless, the knowledge of the potential interactions and effect modifications that type 2 diabetes mellitus can elicit on mortality-associated risk factors is still poorly understood 10. Understanding these is crucial for an optimal approach and adequate guiding of the patient’s management to achieve the expected goals 11. The present study aimed to characterize the risk factors for mortality in patients with heart failure and type 2 diabetes mellitus from RECOLFACA and evaluate the potential effect modifications by type 2 diabetes mellitus over other risk factors.
Materials and methods
Study design and population
The RECOLFACA is a prospective cohort study conducted at 60 medical centers, heart failure clinics, and cardiology outpatient centers in Colombia. Patient enrollment started in February 2017 and ended in October 2019. It included all adult patients (older than 18 years) with a clinical diagnosis of heart failure of any etiology based on the guideline recommendations at the time of inclusion, with at least one hospitalization due to heart failure in the 12 months before enrollment. Specific inclusion and exclusion criteria, along with additional methodologic characteristics of the registry, are described elsewhere 12,13.
Data collection
Information regarding sociodemographic, clinical, and laboratory variables was registered at baseline. Type 2 diabetes mellitus diagnosis was based on self-report, laboratory test results (fasting glucose level > 125 mg/dl or glycated hemoglobin [HbA1c] of more than 7%), or glucose-lowering therapy use. Heart failure severity was assessed using the New York Heart Association (NYHA) classification.
An ischemic disease diagnosis was registered if the patient underwent a coronary revascularization procedure or if a previous myocardial infarction history was present. The following comorbidities were assessed: chronic kidney disease, arterial hypertension, atrial fibrillation, chronic obstructive pulmonary disease (COPD), thyroid disease, and dyslipidemia. The estimated glomerular filtration rate (eGFR) was calculated with the MDRD formula, and an eGFR < 60 ml/min/1.73 m2 was considered the cut-off for chronic kidney disease. Available data on additional echocardiographic variables was registered. The left ventricle ejection fraction variable was available from 2041 patients (81.2%), 502 from the type 2 diabetes mellitus group (80.9%) and 1539 from the non-type 2 diabetes mellitus group (81.3%), the systolic diameter of the left ventricle variable was available from 1305 patients (51.9%), 299 from the type 2 diabetes mellitus group (48.2%) and 1006 from the non-type 2 diabetes mellitus group (53.1%), and the valvular pathology variable was available from all patients. We considered triple therapy as the presence of the prescription of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), plus a beta-blocker and a mineralocorticoid receptor antagonist.
Outcomes
The primary outcome of the study was all-cause mortality. Data on this outcome was collected using a questionnaire applied by each heart failure clinic and center two times per year. The current results represent the data from the follow-up performed after six months of enrollment into the registry. Each center also reviewed each patient’s clinical records to assess specific data about the outcomes.
Statistical analysis
At first, the total sample was divided into two groups (diabetics vs. nondiabetics). Baseline characteristics were described as medians and quartiles for quantitative variables, or absolute counts, proportions and percentages for categorical variables. Differences between groups were assessed using Pearson’s chi square and Fisher’s exact tests for categorical variables and Mann-Whitney U tests for quantitative variables. The cumulative incidence of the mortality events was calculated with their respective 95% confidence intervals. Survival analysis was performed using the Kaplan-Meier method and adjusted Cox proportional hazard models.
A multivariable Cox regression model including all the variables significantly associated with mortality was generated; after this, variables independently associated with this outcome were selected. The final model included all the independent predictors of mortality and was also adjusted by age, sex, chronic kidney disease diagnosis, NYHA classification, and left ventricle ejection fraction. Effect modification was assessed using multiple Cox regression and the Mantel-Haenszel method.
In summary, an effect modifier corresponds to a variable that differentially modifies a risk factor’s observed effect regarding a determined outcome. This results in different risk estimates between the evaluated groups when the effect modifier is present. A p value less than 0.05 (two-tailed test) was considered as statistically significant. All analyses were performed using statistical package Stata™, version 15 (Station College, Texas USA).
Results
From the total 2528 patients included in RECOLFACA between February 2017 and October 2019, 2514 patients had information regarding type 2 diabetes mellitus diagnosis. The prevalence of type 2 diabetes mellitus among these patients was 24.6% (n = 620).
Baseline characteristics
No significant demographic differences were observed between the groups regarding sex, age, and ethnicity (table 1). However, patients with type 2 diabetes mellitus diagnosis had a significantly higher prevalence of hypertension, coronary disease, valvular disease, chronic kidney disease, and dyslipidemia. On the other hand, non-diabetic individuals had more frequently a diagnosis of atrial fibrillation, valvular disease, and Chagas’ disease (table 1). Regarding the pharmacological therapy, patients with type 2 diabetes mellitus diagnosis were more frequently prescribed angiotensin receptor blockers, antiplatelets, and statins, while non-diabetics reported higher use of MRA, ACEI, and digoxin. Finally, diabetic patients showed a lower value of hemoglobin,and glomerular filtration rate while having a higher prevalence of electrolytic disorders.
Table 1. Sociodemographic and clinical characteristics of patients with heart failure diagnosis enrolled in the Registro Colombiano de Insuficiencia Cardíaca (RECOLFACA) by type 2 diabetes mellitus diagnosis.
| Type 2 diabetes mellitus (N = 2514) | |||||
|---|---|---|---|---|---|
| No (n = 1894) n (%) | Yes (n = 620) n (%) | Total n (%) | p value | ||
| Sex | 0.195 | ||||
| Female | 790 (41.7) | 277 (44.7) | 1067 (42.4) | ||
| Male | 1104 (58.3) | 343 (55.3) | 1447 (57.6) | ||
| Age (years) | 69 (59.78) | 69 (62.77) | 69 (59.78) | 0.443 | |
| Race | 0.400 | ||||
| Asian | 0 (0.0) | 1 (0.2) | 1 (0.0) | ||
| White | 85 (4.5) | 31 (5.0) | 116 (4.6) | ||
| Indigenous | 9 (0.5) | 1 (0.2) | 10 (0.4) | ||
| Hispanic | 1398 (73.8) | 455 (73.4) | 1853 (73.7) | ||
| Mestizo | 342 (18.1) | 116 (18.7) | 458 (18.2) | ||
| African-American | 60 (3.2) | 16 (2.6) | 76 (3.0) | ||
| Hypertension | 1283 (67.7) | 528 (85.2) | 1811 (72.0) | < 0.001 | |
| Alcoholism | 69 (3.6) | 17 (2.7) | 86 (3.4) | 0.284 | |
| Cancer | 75 (4.0) | 26 (4.2) | 101 (4.0) | 0.797 | |
| Depression | 34 (1.8) | 13 (2.1) | 47 (1.9) | 0.630 | |
| Dementia | 17 (0.9) | 5 (0.8) | 22 (0.9) | 0.833 | |
| Coronary disease | 482 (25.4) | 224 (36.1) | 706 (28.1) | < 0.001 | |
| COPD | 328 (17.3) | 113 (18.2) | 441 (17.5) | 0.606 | |
| Atrial fibrillation | 456 (24.1) | 104 (16.8) | 560 (22.3) | < 0.001 | |
| Thyroid disease | 279 (14.7) | 109 (17.6) | 388 (15.4) | 0.088 | |
| Chronic kidney disease | 257 (13.6) | 177 (28.5) | 434 (17.3) | < 0.001 | |
| Valvular disease | 342 (18.1) | 87 (14.0) | 429 (17.1) | 0.021 | |
| Smoking habits (former or current) | 341 (18) | 112 (18.1) | 453 (18) | 0.836 | |
| CABG | 109 (5.8) | 61 (9.8) | 170 (6.8) | < 0.001 | |
| Dyslipidemia | 427 (22.5) | 220 (35.5) | 647 (25.7) | < 0.001 | |
| Ischaemic heart disease | 475 (25.1) | 218 (35.2) | 693 (27.6) | < 0.001 | |
| Chagas’ disease | 76 (4.0) | 12 (1.9) | 88 (3.5) | 0.015 | |
| NYHA | 0.094 | ||||
| I | 241 (12.7) | 57 (9.2) | 298 (11.9) | ||
| II | 998 (52.7) | 352 (56.8) | 1350 (53.7) | ||
| III | 565 (29.8) | 182 (29.4) | 747 (29.7) | ||
| IV | 90 (4.8) | 29 (4.7) | 119 (4.7) | ||
| ACC/AHA classification | |||||
| C | 1792 (94.6) | 585 (94.4) | 2377 (94.6) | 0.805 | |
| D | 102 (5.4) | 35 (5.7) | 137 (5.5) | ||
| ACEI | 674 (35.6) | 172 (27.7) | 846 33.7) | < 0.001 | |
| ARB | 766 (40.4) | 303 (48.9) | 1069 (42.5) | < 0.001 | |
| Diuretics | 1257 (66.4) | 436 (70.3) | 1693 (67.3) | 0.068 | |
| Beta-blockers | 1639 (86.5) | 550 (88.7) | 2189 (87.1) | 0.162 | |
| ARNI | 176 (9.3) | 69 (11.1) | 245 (9.7) | 0.181 | |
| MRA | 1082 (57.1) | 317 (51.1) | 1399 (55.6) | 0.009 | |
| Ivabradine | 111 (5.9) | 39 (6.3) | 150 (5.9) | 0.790 | |
| Digoxin | 206 (10.9) | 45 (7.3) | 251 (10.0) | 0.009 | |
| Nitrates | 62 (3.3) | 29 (4.7) | 91 (3.6) | 0.104 | |
| Antiagregants | 804 (42.4) | 356 (57.4) | 1160 (46.1) | < 0.001 | |
| Statins | 984 (52.0) | 407 (65.6) | 1391 (55.3) | < 0.001 | |
| Anticoagulants | 506 (26.7) | 137 (22.1) | 643 (25.6) | 0.022 | |
| Pacemaker | 0.975 | ||||
| Dual-chamber | 73 (3.9) | 25 (4.0) | 98 (3.9) | ||
| Single-chamber | 37 (2.0) | 12 (1.9) | 49 (2.0) | ||
| Other implantable devices | 0.826 | ||||
| ICD | 286 (15.1) | 84 (13.6) | 370 (14.7) | ||
| Resynchronization therapy | 35 (1.8) | 13 (2.1) | 48 (1.9) | ||
| ICD + resynchronization therapy | 98 (5.2) | 29 (4.7) | 127 (5.1) | ||
| Sinus rhythm | 636 (33.6) | 231 (37.3) | 867 (34.5) | 0.094 | |
| QRS complex | |||||
| < 120 ms | 633 (33.4) | 200 (32.3) | 833 (33.1) | 0.785 | |
| > 120 ms | 42 (2.2) | 17 (2.7) | 59 (2.3) | ||
| LV diastolic diameter | 57 (48-65) | 55 (48-63) | 57 (48-65) | 0.045 | |
| LVEF | 32 (25-42) | 33 (25-42) | 33 (25-42) | 0.645 | |
| Hemoglobin (mg/dl) | 13 (12.14) | 12 (11.14) | 13 (12.14) | < 0,001 | |
| Anemia | 494 (35.4) | 232 (48.3) | 726 (38.7) | < 0,001 | |
| Serum creatinine | 1.1 (0.9-1.35) | 1.2 (0.9-1.6) | 1.1 (0.9-1.4) | < 0,001 | |
| GFR (ml/min/1,73 m3) | 59 (44.78) | 53 (36.74) | 57 (43.77) | < 0,001 | |
| Hyponatremia | 1079 (56.9) | 390 (62.9) | 240 (9.5) | < 0,001 | |
| Hyperkalemia | 113 (8.3) | 63 (12.6) | 176 (9.4) | 0,005 | |
| NT-proBNP | 2151 (855-5089) | 2795 (1002-6857) | 2255 (950-5594) | 0,101 | |
COPD: Chronic obstructive pulmonary disease; CABG: Coronary artery bypass grafting; NYHA: New York Heart Association; ACC/AHA: American College of Cardiology/American Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blockers; ARNI: Angiotensin receptor-neprilysin inhibitor; MRA: Mineralocorticoid receptor antagonist; ICD: Implantable cardioverter defibrillator; LV: Left ventricle; LVEF: Left ventricular ejection fraction; GFR: Glomerular filtration rate; NT-proBNP: N-terminal pro b-type natriuretic peptide
Mortality and associated factors
The median follow-up time was 215 days (Q1: 188; Q3: 254). A total of 170 patients (6.76%) died during the follow-up, for a mortality rate of 0.29 per 1,000 person-years (95% CI: 25.4-34.5). Significantly higher mortality was observed in the type 2 diabetes mellitus group than in the non-diabetic group (8.9% vs. 6.1%, respectively; p = 0.016). Supplementary table 1 summarizes the association between the evaluated variables and mortality use a bivariate analysis. From these variables, we included those that were significantly associated with mortality in the multivariable Cox regression model. Finally, after adjusting by age, sex, type 2 diabetes mellitus, bchronic kidney disease, NYHA classification, and left ventricle ejection fraction, seven independent predictors of short-term mortality were identified (table 2).
Table 2. Factors independently associated with short-term mortality in the current cohort of heart failure patients. The logistic regression model was also adjusted by age, sex, chronic kidney disease, New York Heart Association classification, and left ventricular ejection fraction.
| Factor | Hazard ratio (95% CI) | P value |
|---|---|---|
| COPD | 1.76 (1.03-3.02) | 0.039 |
| Sinus rhythm | 0.56 (0.34-0.92) | 0.022 |
| Triple therapy | 0.41 (0.23-0.73) | 0.003 |
| Nitrates use | 3.01 (1.19-7.63) | 0.020 |
| Statins use | 0.48 (0.28-0.80) | 0.005 |
| Anemia | 1.85 (1.12-3.04) | 0.016 |
| Hyperkalemia | 3.09 (1.64-5.83) | 0.001 |
CI: Confidence interval; COPD: Chronic obstructive pulmonary disease
Furthermore, we also analyzed the variables associated with mortality in the type 2 diabetes mellitus subgroup (table 3). In this specific sub-group, only chronic kidney disease, smoking status, statins use, anticoagulants use, left ventricle diastolic diameter, and anemia were significantly associated with the mortality outcome, being some of these factors different from those observed in the general cohort. The multivariate analysis showed that only the left ventricle diastolic diameter was an independent mortality predictor in the type 2 diabetes mellitus group (HR = 0.96; 95% CI: 0.93-0.98).
Table 3. A bivariate analysis evaluating the association between the sociodemographic and clinical variables with short-term all-cause mortality in patients with type 2 diabetes mellitus diagnosis of the Registro Colombiano de Insuficiencia Cardíaca (RECOLFACA).
| Alive (n = 565) n (%) | Dead (n =55) n (%) | Total (N = 620) n (%) | p value | ||
|---|---|---|---|---|---|
| Sex | |||||
| Female | 250 (44.25) | 27 (49.09) | 277 (44.68) | 0.490 | |
| Male | 315 (55.75) | 28 (50.91) | 343 (55.32) | ||
| Age (years) | 69 (62.77) | 69 (63.79) | 69 (62.77) | 0.453 | |
| Race | |||||
| Asian | 1 (0.18) | 0 (0) | 1 (0.16) | ||
| White | 29 (5.13) | 2 (3.64) | 31 (5) | ||
| Indigenous | 1 (0.18) | 0 (0) | 1 (0.16) | 0.167 | |
| Hispanic | 420 (74.34) | 35 (63.64) | 455 (73.39) | ||
| Mestiza | 102 (18.05) | 14 (25.45) | 116 (18.71) | ||
| African-American | 12 (2.12) | 4 (7.27) | 16 (2.58) | ||
| Hypertension | 478 (84.60) | 50 (90.91) | 528 (85.16) | 0.209 | |
| Current alcoholism | 14 (2.48) | 3 (5.45) | 17 (2.74) | 0.197 | |
| Cancer | 21 (3.72) | 5 (9.09) | 26 (4.19) | 0.058 | |
| Coronary disease | 200 (35.40) | 24 (43.64) | 224 (36.13) | 0.225 | |
| COPD | 99 (17.52) | 14 (25.45) | 113 (18.23) | 0.146 | |
| Atrial fibrillation | 92 (16.28) | 12 (21.82) | 104 (16.77) | 0.294 | |
| Thyroid disease | 96 (16.99) | 13 (23.64) | 109 (17.58) | 0.216 | |
| Chronic kidney disease | 153 (27.08) | 24 (43.64) | 177 (28.55) | 0.009 | |
| Valvular disease | 80 (14.16) | 7 (12.73) | 87 (14.03) | 0.770 | |
| Smoking habits (former or current) | 96 (16.99) | 16 (29.09) | 112 (18.06) | 0.026 | |
| CABG | 57 (10.09) | 4 (7.27) | 61 (9.84) | 0.503 | |
| Dyslipidemia | 206 (36.46) | 14 (25.45) | 220 (35.48) | 0.103 | |
| Chagas disease | 11 (1.95) | 1 (1.82) | 12 (1.94) | 0.947 | |
| NYHA | |||||
| I | 54 (9.56) | 3 (5.45) | 57 (9.19) | ||
| II | 325 (57.52) | 27 (49.09) | 352 (56.77) | 0.167 | |
| III | 162 (28.67) | 20 (36.36) | 182 (29.35) | ||
| IV | 24 (4.25) | 5 (9.09) | 29 (4.68) | ||
| ACC/AHA classification | |||||
| C | 533 (94.34) | 52 (94.55) | 585 (94.35) | 0.949 | |
| D | 32 (5.66) | 3 (5.45) | 35 (5.65) | ||
| Triple therapy | 242 (42.83) | 24 (43.64) | 266 (42.90) | 0.908 | |
| Diuretics | 391 (69.20) | 45 (81.82) | 436 (70.32) | 0.051 | |
| Digoxin | 40 (7.08) | 5 (9.09) | 45 (7.26) | 0.583 | |
| Nitrates | 24 (4.25) | 5 (9.09) | 29 (4.68) | 0.104 | |
| Antiplatelet | 328 (58.05) | 28 (50.91) | 356 (57.42) | 0.306 | |
| Statins | 380 (67.26) | 27 (49.09) | 407 (65.65) | 0.007 | |
| Anticoagulants | 117 (20.71) | 20 (36.36) | 137 (22.10) | 0.008 | |
| Pacemaker | 0.054 | ||||
| Dual-chamber | 24 (4.25) | 1 (1.81) | 25 (4.42) | ||
| Single-chamber | 9 (1.59) | 3 (5.45) | 12 (2.12) | ||
| Other implantable devices | 0.181 | ||||
| ICD | 94 (16.64) | 12 (21.82) | 106 (17.10) | ||
| Resynchronization therapy | 10 (1.77) | 3 (5.45) | 13 (2.10) | ||
| ICD + resynchronization therapy | 27 (4.78) | 2 (3.62) | 29 (4.68) | ||
| Sinusal rhythm | 213 (68.93) | 18 (72) | 231 (69.16) | 0.749 | |
| Prolonged QRS complex | 126 (40.78) | 8 (32) | 134 (40.12) | 0.389 | |
| LV diastolic diameter | 55 (48.63) | 50.5 (3958) | 55 (4863) | 0.015 | |
| LVEF | 34 (25.43) | 28 (2040) | 33 (2542) | 0.101 | |
| Anemia | 212 (48.51) | 20 (46.51) | 232 (48.33) | 0.007 | |
| Serum creatinine | 1.2 (0.93-1.60) | 1.29 (1.1.8) | 1.2 (0.95-1.61) | 0.409 | |
| GFR (ml/min/1,73 m3) | 53.35 (36.05-75.24) | 52.37 (33.05-66.58) | 53.3 (35.71-74.21) | 0.521 | |
| Hyponatremia | 61 (14.59) | 9 (21.43) | 70 (15.22) | 0.240 | |
| Hyperkalemia | 54 (11.82) | 9 (20.45) | 63 (12.57) | 0.099 | |
| NT-proBNP | 2790 (1099-5896) | 9496 (996- 1671) | 2795 (1002-6857) | 0.254 |
COPD: Chronic obstructive pulmonary disease; CABG: Coronary artery bypass grafting; NYHA: New York Heart Association; ACC/AHA: American College of Cardiology/American Heart Association; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin receptor blockers; ARNI: Angiotensin receptor-neprilysin Inhibitor; MRA: Mineralocorticoid receptor antagonist; ICD: Implantable cardioverter defibrillator; LV: Left ventricle; LVEF: Left ventricular ejection fraction; GFR: Glomerular filtration rate; NT-proBNP: N-terminal pro b-type natriuretic peptide
Interaction and effect modification by diabetes mellitus
There were relevant differences when assessing the independent factors by the type 2 diabetes mellitus group. At first, patients receiving triple medical therapy in the non-type 2 diabetes mellitus group had significantly lower mortality than those not receiving this therapeutic scheme.
On the other hand, the incidence of mortality was not statistically different in the group of patients with type 2 diabetes mellitus (figure 1). A similar result was observed regarding the report of sinus rhythm in the last electrocardiogram performed. No additional significant differences were observed for the other independent predictor variables.
Figure 1. Mortality in patients according to sinus rhythm and triple therapy [angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), beta-blocker and mineralocorticoid receptor antagonist (MRA)] by type 2 diabetes mellitus group.
Despite these findings, there was no evidence of effect modification by type 2 diabetes mellitus on the relationship between any of the independent predictors and all-cause mortality (figure 2). Furthermore, no interaction terms by type 2 diabetes mellitus were observed in the assessed sample (figure 2). Nevertheless, an interesting result was observed when assessing smoking history. Although it was not an independent predictor of short-term mortality in the general cohort, patients with type 2 diabetes mellitus and tobacco consumption (current or former) had a significantly higher risk of mortality (HR = 1.84; 95% CI: 1.01-3.35) while the difference was not statistically significant in non-diabetic individuals (HR = 0.61; 95% CI: 0.35-1.11). Moreover, a significant effect modification by type 2 diabetes mellitus on the association between tobacco consumption and mortality was observed (p value = 0.005), along with a significant interaction term between both variables (p value for interaction = 0.010).
Figure 2. Adjusted association of each independent predictor by type 2 diabetes mellitus group and all-cause mortality. The p value for effect modification was calculated using the Mantel-Haenszel test of homogeneity.
Discussion
In the present study, the differential characteristics of patients with heart failure with and without type 2 diabetes mellitus enrolled in the RECOLFACA were described. Almost one-fourth of the patients with heart failure from the registry had a concomitant diagnosis of type 2 diabetes mellitus, highlighting a lower use of MRA, ACEI, and digoxin in these patients, along with a higher prevalence of chronic kidney disease, anemia, and electrolytic disorders. Finally, type 2 diabetes mellitus had a higher risk of mortality in the univariate analysis. Only COPD, nitrate use, anemia, and hyperkalemia were independently associated with higher mortality risk in the general cohort. In contrast, sinus rhythm, triple therapy with ACEI/ARB, MRA and beta-blockers, and statin use were associated with a lower risk of this outcome. Regarding the type 2 diabetes mellitus group, only left ventricle diastolic diameter was independently associated with mortality.
Finally, in our registry, type 2 diabetes mellitus diagnosis did not modify the effect of independent predictors of all-cause mortality in patients with heart failure after adjusting by relevant sociodemographic and clinical variables. Likewise, several studies have evaluated the potential effect modification that type 2 diabetes mellitus could exert in different contexts, but only some of those performed in cardiovascular disease settings have reported that type 2 diabetes mellitus does not modify mortality risk when several risk factors are present 10,14,15. The study by Selvarajah et al.10, which evaluated patients with cardiovascular disease, observed that type 2 diabetes mellitus diagnosis did not modify the effect of renal impairment with all-cause mortality after a follow-up of 33.198 person-years. Similarly, Gerstein et al.14 observed that microalbuminuria was an independent risk factor for all-cause mortality both in patients with and without type 2 diabetes mellitus diagnosis. On the other hand, Ahmed et al.15 reported that type 2 diabetes mellitus modified the effect of eGFR regarding all-cause mortality risk; however, their analysis was not adjusted by albuminuria, which precluded a more precise assessment due to the impact of albuminuria in the risk of mortality.
In regard to the higher mortality found in the type 2 diabetes mellitus group when compared to non-diabetics, our results coincide with those reported in the meta-analysis performed by Dauriz et al.16, where they found approximately 30% increased risk of all-cause death. Moreover, they reported that nearly one-quarter of the patients with heart failure had diabetes, similar to what we reported in the RECOLFACA. The AMERICCAASS is a recent registry that also included heart failure patients older than 18 years, that reported a similar finding of 28% patients with heart failure and diabetes in their results from the first 1,000 patients enrolled from different Latin American countries, including Colombia 17. Another large registry that analyzed data from more than 45,000 patients from different continents, including Latin America, was the Reduction of Atherothrombosis for Continued Health (REACH) registry, where approximately 30% of increased mortality in diabetic group vs. non-diabetics was also found. However, the inclusion criteria of the REACH registry are different from ours as they not only included patients older than 18 years with heart failure, but all patients > 45 years old that had established atherosclerosis or ≥ 3 risk factors for atherosclerosis, hence, the results are not comparable to ours.
In our study patients with type 2 diabetes mellitus and tobacco consumption had a significantly higher risk of mortality. A related finding was reported by the study of Jeong et al.18 where they analyzed data from 349,137 type 2 diabetes mellitus Korean patients with current or history of smoking. In their study they reported that smoking cessation was associated with a 10% lower risk of all-cause mortality. However, contrary to our study, the population they studied did not have heart failure as a baseline condition, hence, our results are not completely comparable. This could suggest that the higher risk of mortality seen between patients with type 2 diabetes mellitus and tobacco consumption (current or former), has no direct relation to the heart failure diagnosis they had.
Our results regarding the variables that are independently associated with higher mortality risk in the general cohort coincide with previous reports. Although few studies have analyzed the prognosis of patients with heart failure and COPD, it has been reported as an independent predictor of death and heart failure hospitalization when reported in multivariable models 19. Only one study has explored the causes of increased mortality 20.
According to a study with 4606 acute care patients with congestive heart failure, the use nitrates is associated with increased relative risk of in-hospital mortality 21. Anemia has been found as an independent predictor by multiple studies, including the study by Gupta et al.22 where they found that anemia emerged as an independent predictor of all-cause mortality and heart failure hospitalizations at the end of the follow-up, and the recent study by Köseoğlu et al.23 who found similar results. Lastly, hyperkalemia is a known risk factor for mortality among critically ill patients and cardiac patients 24.
The systematic review of Girerd et al.25 showed that the benefits of heart failure treatment appear to be similar in patients with type 2 diabetes mellitus as in non-diabetic patients, suggesting a lack of effect modification by this condition.
However, Kroon et al.26 assessed the potential effect modification by type 2 diabetes mellitus in the association between B-type natriuretic peptide (BNP) and changes in left ventricular function markers in patients with incipient heart failure. In this study, type 2 diabetes mellitus modified BNP’s effect over left ventricular mass index, left atrial volume * left ventricular mass index, and E/e’ ratio, even after adjustment by sex, age, baseline left ventricular mass index, body mass index, and use of antihypertensives.
Finally, Ebong et al.27 reported that type 2 diabetes mellitus, independently of its treatment and severity, modified the effect of the association between lipid fractions and incident heart failure, potentially due to the pathophysiological process of glucolipotoxicity. Although in our study type 2 diabetes mellitus was identified as a significant effect modifier of the impact of smoking habits and mortality, there are no previous reports on this specific topic. However, it is worth mentioning that cigarette smoking has been identified as a contributor to all-cause mortality the general population, which is expected to be similar in type 2 diabetes mellitus patients 28. Moreover, among type 2 diabetes mellitus patients, cigarette smoking may accelerate cardiovascular disease mortality 29,30.
Regarding treatment, for several years, there were concerns about the use of beta-blockers in patients with type 2 diabetes mellitus due to the perceived risk of hypoglycemia, limiting their use in patients with heart failure and type 2 diabetes mellitus despite the benefit observed in heart failure trials 25,31. Furthermore, several clinical trials have reported that the impact of heart failure medical therapy on prospective outcomes in patients with type 2 diabetes mellitus could be significantly different from the one observed in non-diabetic patients 32. Unfortunately, some of these trials were performed in the 80s and 90s; thus, these studies did not assess interactions and effect modifications.
A recent post-hoc analyses and meta-analyses have suggested that the efficacy of the therapy with ACEI/ARB, MRA, and beta-blockers is similar in heart failure patients with and without type 2 diabetes mellitus, observations that are consistent with the results of the present study 33-36. These findings’ relevance lies in the possibility of promoting an optimal medical treatment for patients with heart failure despite being diabetic or not 37. To achieve this goal, non-cardiologists who treat patients with heart failure and type 2 diabetes mellitus should be invited to actively participate in the therapeutic optimization process and patient referral to specialized centers for interventional strategies. The involvement of nurses, general practitioners, internal medicine specialists, endocrinologists, and diabetologists in the process of up-titration of heart failure medications has been shown to be safe and efficient in achieving target doses of ACEI/ARB, MRA, and beta-blockers 36-38.
Finally, our findings showed that several comorbidities and clinical conditions were independently associated with a higher risk of short-term mortality in heart failure patients, which is consistent with the literature 39-42. The effect of these conditions on short term mortality risk was not modified by type 2 diabetes mellitus; nonetheless, we observed a significant effect modification by type 2 diabetes mellitus in the association between smoking status and mortality. This finding may derive from the common pathophysiological processes that both type 2 diabetes mellitus and smoking promote, which results in a higher incidence of macrovascular and microvascular complications due to a synergistic negative effect of these two conditions combined 43,44.
Limitations of the study
The present study had from several limitations. The RECOLFACA does not collect information regarding HbA1C levels or antidiabetic treatment; therefore, adjustment by these important variables was not possible. Moreover, no information was available on the duration and severity of type 2 diabetes mellitus, including organ involvement. In addition, only a short follow-up was available for the analyses, therefore limiting the precision of the calculated estimates. Lack of power could have been an issue in the present study, potentially leading to false non-significance when the interaction terms and effect modifications were assessed. Moreover, several potential sources of variation were not accounted for in the present study such as body mass index or other relevant diagnoses like asthma. Finally, it was not possible to have data from all patients regarding echocardiographic variables which could be a confounding factor. Therefore, our results should be interpreted with caution.
RECOLFACA is the largest multicentric registry from Colombian patients with heart failure. In this registry, patients with type 2 diabetes mellitus were less frequently treated with MRA, ACEI, and digoxin than non-diabetics while having a higher mortality rate. Moreover, several clinical conditions were independently associated with mortality in this registry. Our results also suggest that type 2 diabetes mellitus diagnosis does not modify the effect of the independent risk factors for mortality in heart failure evaluated. However, type 2 diabetes mellitus was observed to significantly modify the risk relation between mortality and smoking in patients with heart failure.
Competency in patient care and procedural skills: patients with heart failure and type 2 diabetes mellitus in Colombia are less frequently treated with important heart failure drugs compared to non-diabetics, highlighting the need of optimizing the pharmacological therapy in this population. Finally, although type 2 diabetes mellitus did not modify the effect of mortality risk factors in heart failure, it seems it can elicit a relevant effect modification in the relationship between smoking history and mortality.
Translational outlook: Further research is needed to assess the role of tipe 2 diabetes mellitus as an effect modifier for risk factors of all-cause mortality in heart failure patients.
Acknowledgments
List of members of the RECOLFACA Group
Alberto Cadena, Clínica de la Costa, Barranquilla, Colombia
Alejandro D. Ochoa-Morón, Instituto Cardiovascular del Cesar - ICVC, Cesar, Colombia
Alejandro Posada-Bastidas, Centro Cardiovascular Somer Incare, Rionegro, Colombia
Álex Rivera-Toquica, Centro Médico para el Corazón, Clínica los Rosales, Universidad Tecnológica de Pereira, Pereira, Colombia
Alexis Llamas, Clínica Las Américas, Medellín, Colombia
Alfonso Muñoz-Velásquez, Institución Clínica Iberoamérica, Barranquilla, Colombia Álvaro H. Rodríguez-Cerón, Hospital Cardiovascular de Cundinamarca, Soacha, Colombia
Andrés F. Buitrago, Fundación Santa Fe, Bogotá, Colombia
Ángel A. García-Peña, Hospital Universitario San Ignacio, Bogotá, Colombia
Argemiro R. Martínez-Carvajal, Hospital Departamental Tomás Uribe Uribe, Tuluá, Colombia
Armando Alcalá-Hernández, Procardio Caribe S.A.S., Barranquilla, Colombia
Balkis Rolong, Cardiología Integral, Barranquilla, Colombia
Carlos A. Rentería-Asprilla, Cardiodiagnóstico del Chocó, Quibdó, Colombia
Carlos A. Arias-Barrera, Clínica Universitaria Colombia Colsanitas, Bogotá, Colombia
Carlos A. Plata-Mosquera, Dime Clínica Neuro Cardiovascular, Cali, Colombia
Clara I. Saldarriaga-Giraldo, Clínica Cardio VID, Universidad de Antioquia, Medellín, Colombia
Claudia Victoria Anchique, Mediagnóstica, Duitama, Colombia
Diego H. Hoyos-Ballesteros, Centro Cardiovascular & Diabetes MASSALUD, Armenia, Colombia
Edgar E. Castro-Osorio, SES Hospital Universitario de Caldas, Manizales, Colombia
Eduardo J. Echeverri-Navarrete, Clínica de Occidente, Cali, Colombia
Elkin G. Ramírez-Puentes, Sociedad Cardiológica Colombiana S.A.S., Villavicencio, Colombia
Erika Martínez, IPS Salud Social, Barranquilla, Colombia
Fernán Mendoza-Beltrán, Fundación Clínica Shaio, Bogotá, Colombia
Fernando Manzur-Jatín, Centro Diagnóstico Cardiológico, Cartagena, Colombia
Fernando Rivera-Toquica, Virrey Solís IPS, Cali, Colombia
Gary A. Baquero-Lozano, Hospital Santa Clara, Bogotá, Colombia
Guillermo Trout Guardiola, Grupo Salud IPS, Santa Marta, Colombia
Gustavo Moreno-Silgado, Hospicardio, Montería, Colombia
Hugo E. Osorio-Carmona, Clínica Medilaser Neiva, Neiva, Colombia
Jannes Buelvas-Herazo, Cardiodiagnóstico S.A., Barranquilla, Colombia
Jorge A. Sandoval-Luna, Cardiología Siglo XXI, Ibagué, Colombia
José I. Mosquera-Jiménez, Unidad Cardiológica del Cauca Única S.A.S.,
Popayán, Colombia
José L. Accini-Mendoza, Centro Científico Asistencial IPS S.A.S., Barranquilla, Colombia
Juan A. Cerón, Unimedic IPS, Pasto, Colombia
Juan C. García, Hospital Universidad del Norte, Barranquilla, Colombia
Juan C. Ortega-Madariaga, Hospital Universitario Erasmo Meoz, Cúcuta, Colombia
Juan D. López-Ponce de León, Fundación Valle de Lili, Cali, Colombia
Juan F. Carvajal-Estupiñán, Instituto del Corazón de Bucaramanga, Bucaramanga, Colombia
Julián R. Lugo-Peña, Clínicos IPS, Bogotá, Colombia
Julián Vanegas-Eljach, Clínica Avidanti, Manizales, Colombia
Lisbeth N. Morales-Rodríguez, Clínica Medilaser, Tunja, Colombia
Luis E. Echeverría-Correa, Fundación Cardiovascular de Colombia, Floridablanca, Colombia
Luis M. Ávila-Barros, Clínica Riohacha, Riohacha, Colombia
Luis Silva-Díaz-Granados, Clínica Chía, Chía, Colombia
Luz C. Zárate-Correa, Clínica Imbanaco, Hospital Universitario del Valle, Cali, Colombia
Marco A. De León-Espitia, Cardio Care Colombia SAS, Montería, Colombia
Mario H. Zarama-Márquez, Clínica Nuestra Señora de Fátima, Pasto, Colombia
Nelly Velásquez-López, Clínica Medellín, Medellín, Colombia
Nelson A. López-Garzón, Hospital Universitario San José, Popayán, Colombia
Nelson E. Murillo-Benítez, Angiografía de Occidente, Cali, Colombia
Óscar A. Pacheco-Jiménez, Hospital Militar Central, Bogotá, Colombia
Óscar S. Rincón-Peña, Unidad de Diagnóstico Cardiovascular Sveins, Duitama, Colombia
Patricia Rodríguez-Gómez, Unidad Cardiológica de Cartagena, Cartagena, Colombia
Rafael I. Bustamante-Urzola, Rafael Bustamante y Compañía Ltda., Leticia, Colombia
Ricardo Gómez-Paláu, Clínica Amiga, Cali, Colombia
Rolando Palacio, Clínica Renacer, Riohacha, Colombia
Sebastián Campbell-Quintero, Clínica Mediláser, Florencia, Colombia
Silfriedo Arrieta-González, Hospital Universitario de Sincelejo, Sincelejo, Colombia
Viviana Quintero-Yepes, Clínica El Rosario, Medellín, Colombia
RECOLFACA research group*
* The list of all investigators from the RECOLFACA group is presented at the end of this manuscript in the acknowledgments section
Citation: Echeverría LE, Saldarriaga C, Campbell-Quintero S, Morales-Rodríguez LN, López-Ponce de León JD, Buitrago AF, et al. Diabetes mellitus in patients with heart failure and effect modification of risk factors for short-term mortality: An observational study from the Registro Colombiano de Falla Cardíaca (RECOLFACA). Biomédica. 2024;44(Supl.1):182-97. https://doi.org/10.7705/biomedica.6951
Author's contributions:
Luis Eduardo Echeverría, Juan Esteban GómezMesa, Clara Saldarriaga and Alex Arnulfo Rivera-Toquica: conceptualization, formal analysis, funding acquisition, investigation, methodology, project administration, resources, and visualization.
Juan Esteban Gómez-Mesa: contributed to data curation, software management, supervision, and validation.
Funding:
No funding bodies had any role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Tousoulis D, Oikonomou E, Siasos G, Stefanadis C. Diabetes mellitus and heart failure. Eur Cardiol. 2014;9:37–42. doi: 10.15420/ecr.2014.9.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ciapponi A, Alcaraz A, Calderón M, Matta MG, Chaparro M, Soto N, et al. Burden of heart failure in Latin America: A systematic review and meta-analysis. Rev Esp Cardiol. 2016;69:1051–1060. doi: 10.1016/j.rec.2016.04.054. [DOI] [PubMed] [Google Scholar]
- 3.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation. 2020;141:e139-596. doi: 10.1161/CIR.0000000000000757. [DOI] [PubMed] [Google Scholar]
- 4.Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107–111. doi: 10.2991/jegh.k.191028.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Card Fail Rev. 2017;3:52–55. doi: 10.15420/cfr.2016:20:2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Kasznicki J, Drzewoski J. Heart failure in the diabetic population - pathophysiology, diagnosis and management. Arch Med Sci. 2014;10:546–556. doi: 10.5114/aoms.2014.43748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Qazi MU, Malik S. Diabetes and cardiovascular disease: Original insights from the Framingham Heart Study. Glob Heart. 2013;8:43–48. doi: 10.1016/j.gheart.2012.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ziaeian B, Hernández AF, DeVore AD, Wu J, Xu H, Heidenreich PA, et al. Long-term outcomes for heart failure patients with and without diabetes: From the Get with the Guidelines-Heart Failure Registry. Am Heart J. 2019;211:1–10. doi: 10.1016/j.ahj.2019.01.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Win TT, Davis HT, Laskey WK. Mortality among patients hospitalized with heart failure and diabetes mellitus: Results from the National Inpatient Sample 2000-2010. Circ Heart Fail. 2016;9:e003023. doi: 10.1161/CIRCHEARTFAILURE.115.003023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Selvarajah S, Uiterwaal CSPM, Haniff J, van der Graaf Y, Visseren FLJ, Bots ML, et al. Renal impairment and all-cause mortality in cardiovascular disease: Effect modification by type 2 diabetes mellitus. Eur J Clin Invest. 2013;43:198–207. doi: 10.1111/eci.12035. [DOI] [PubMed] [Google Scholar]
- 11.Bauters C, Lamblin N, Mc Fadden EP, van Belle E, Millaire A, de Groote P. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol. 2003;2:1–1. doi: 10.1186/1475-2840-2-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Gómez-Mesa JE, Grupo Investigador RECOLFACA Registro Colombiano de Falla Cardíaca (RECOLFACA): resultados. Rev Colomb Cardiol. 2021;28:334–342. [Google Scholar]
- 13.Gómez-Mesa JE, RECOLFACA research group Colombian heart failure registry (RECOLFACA): Methodology and preliminary data. Rev Colomb Cardiol. 2021;28:217–230. [Google Scholar]
- 14.Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426. doi: 10.1001/jama.286.4.421. [DOI] [PubMed] [Google Scholar]
- 15.Ahmed S, Cannon CP, Giugliano RP, Murphy SA, Morrow DA, Antman EM, et al. The independent and combined risk of diabetes and non-endstage renal impairment in non-ST- segment elevation acute coronary syndromes. Int J Cardiol. 2008;131:105–112. doi: 10.1016/j.ijcard.2007.09.006. [DOI] [PubMed] [Google Scholar]
- 16.Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, et al. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: A metaanalysis. Diabetes Care. 2017;40:1597–1605. doi: 10.2337/dc17-0697. [DOI] [PubMed] [Google Scholar]
- 17.Gómez-Mesa JE, Gutiérrez-Posso JM, Escalante-Forero M, Córdoba-Melo BD, Cárdenas-Marín PA, Perna ER, et al. American registry of ambulatory or acutely decompensated heart failure (AMERICCAASS Registry): First 1000 patients. Clin Cardiol. 2024;47:e24182. doi: 10.1002/clc.24182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Jeong SM, Yoo JE, Park J, Jung W, Lee KN, Han K, et al. Smoking behavior change and risk of cardiovascular disease incidence and mortality in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2023;22:193–193. doi: 10.1186/s12933-023-01930-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. [DOI] [Google Scholar]
- 20.Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, et al. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: Data from the Val-HeFT heart failure trial. J Card Fail. 2007;13:797–804. doi: 10.1016/j.cardfail.2007.07.012. [DOI] [PubMed] [Google Scholar]
- 21.Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators Arch Intern Med. 1996;156:1669–1673. [PubMed] [Google Scholar]
- 22.Gupta K, Kalra R, Rajapreyar I, Joly JM, Pate M, Cribbs MG, Ather S, et al. Anemia, mortality, and hospitalizations in heart failure with a preserved ejection fraction (from the TOPCAT Trial) Am J Cardiol. 2020;125:1347–1354. doi: 10.1016/j.amjcard.2020.01.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Köseoğlu FD, Özlek B. Anemia and iron deficiency predict all-cause mortality in patients with heart failure and preserved ejection fraction: 6-year follow-up study. Diagnostics (Basel) 2024;14:209–209. doi: 10.3390/diagnostics14020209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Brueske B, Sidhu MS, Schulman-Marcus J, Kashani KB, Barsness GW, Jentzer JC. Hiperkalemia is associated with increased mortality among unselected cardiac intensive care unit patients. J Am Heart Assoc. 2019;8:e011814. doi: 10.1161/JAHA.118.011814. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Girerd N, Zannad F, Rossignol P. Review of heart failure treatment in type 2 diabetes patients: It’s at least as effective as in non-diabetic patients! Diabetes Metab. 2015;41:446–455. doi: 10.1016/j.diabet.2015.06.004. [DOI] [PubMed] [Google Scholar]
- 26.Kroon MH, van den Hurk K, Alssema M, Kamp O, Stehouwer CDA, Henry RMA, et al. Prospective associations of B-type natriuretic peptide with markers of left ventricular function in individuals with and without type 2 diabetes: An 8-year follow-up of the Hoorn Study. Diabetes Care. 2012;35:2510–2514. doi: 10.2337/dc11-1959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Ebong IA, Goff DC, Rodríguez CJ, Chen H, Sibley CT, Bertoni AG. Association of lipids with incident heart failure among adults with and without diabetes mellitus: Multiethnic Study of Atherosclerosis. Circ Heart Fail. 2013;6:371–378. doi: 10.1161/CIRCHEARTFAILURE.112.000093. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Cho MH, Lee K, Park SM, Chang J, Choi S, Kim K, et al. Effects of smoking habit change on all-cause mortality and cardiovascular diseases among patients with newly diagnosed diabetes in Korea. Sci Rep. 2018;8:5316–5316. doi: 10.1038/s41598-018-23729-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Suárez L, Barrett-Connor E. Interaction between cigarette smoking and diabetes mellitus in the prediction of death attributed to cardiovascular disease. Am J Epidemiol. 1984;120:670–675. doi: 10.1093/oxfordjoumals.aje.a113933. [DOI] [PubMed] [Google Scholar]
- 30.Gambaro G, Bax G, Fusaro M, Normanno M, Manani SM, Zanella M, et al. Cigarette smoking is a risk factor for nephropathy and its progression in type 2 diabetes mellitus. Diabetes Nutr Metab. 2001;14:337–342. [PubMed] [Google Scholar]
- 31.Chen J, Marciniak TA, Radford MJ, Wang Y, Krumholz HM. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients: Results from the national cooperative cardiovascular project. J Am Coll Cardiol. 1999;34:1388–1394. doi: 10.1016/s0735-1097(99)00383-6. [DOI] [PubMed] [Google Scholar]
- 32.Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J. 2003;146:848–853. doi: 10.1016/S0002-8703(03)00403-4. [DOI] [PubMed] [Google Scholar]
- 33.Shekelle PG, Rich MW, Morton SC, ColSW Atkinson, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A metaanalysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–1538. doi: 10.1016/s0735-1097(03)00262-6. [DOI] [PubMed] [Google Scholar]
- 34.MacDonald MR, Petrie MC, Varyani F, Östergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29:1377–1385. doi: 10.1093/eurheartj/ehn153. [DOI] [PubMed] [Google Scholar]
- 35.Erland E, Philippe L, Patricia V, Hermann W. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001;3:469–479. doi: 10.1016/S1388-9842(01)00174-X. [DOI] [PubMed] [Google Scholar]
- 36.Rickli H, Steiner S, Müller K, Hess OM. Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial) Eur J Heart Fail. 2004;6:761–768. doi: 10.1016/j.ejheart.2003.11.025. [DOI] [PubMed] [Google Scholar]
- 37.Doughty RN, Wright SP, Pearl A, Walsh HJ, Muncaster S, Whalley GA, et al. Randomized, controlled trial of integrated heart failure management. The Auckland Heart Failure Management Study. Eur Heart J. 2002;23:139–146. doi: 10.1053/euhj.2001.2712. [DOI] [PubMed] [Google Scholar]
- 38.Driscoll A, Srivastava P, Toia D, Gibcus J, Hare DL. A nurse-led up-titration clinic improves chronic heart failure optimization of beta-adrenergic receptor blocking therapy--a randomized controlled trial. BMC Res Notes. 2014;7:668–668. doi: 10.1186/1756-0500-7-668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJV. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11:130–139. doi: 10.1093/eurjhf/hfn013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.De Blois J, Simard S, Atar D, Agewall S. Norwegian Heart Failure Registry. COPD predicts mortality in HF: The Norwegian Heart Failure Registry. J Card Fail. 2010;16:225–229. doi: 10.1016/j.cardfail.2009.12.002. [DOI] [PubMed] [Google Scholar]
- 41.Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. doi: 10.1016/j.jacc.2008.04.061. [DOI] [PubMed] [Google Scholar]
- 42.Chairat K, Rattanavipanon W, Tanyasaensook K, Chindavijak B, Chulavatnatol S, Nathisuwan S. Relationship of anemia and clinical outcome in heart failure patients with preserved versus reduced ejection fraction in a rural area of Thailand. Int J Cardiol Heart Vasc. 2020;30:100597–100597. doi: 10.1016/j.ijcha.2020.100597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Pan A, Wang Y, Talaei M, Hu FB. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: A meta-analysis and systematic review. Circulation. 2015;132:1795–1804. doi: 10.1161/CIRCULATIONAHA.115.017926. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Campagna D, Alamo A, Di Pino A, Russo C, Calogero AE, Purrello F, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr. 2019;11:85–85. doi: 10.1186/s13098-019-0482-2. [DOI] [PMC free article] [PubMed] [Google Scholar]